Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial-Reference-Cited by-同舟云学术

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial

Published:2012-12 Issue:12 Volume:18 Page:1859-1866
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Solomon Scott R.,Sizemore Connie A.,Sanacore Melissa,Zhang Xu,Brown Stacey,Holland H. Kent,Morris Lawrence E.,Bashey Asad

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference26 articles.

1. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings;Szydlo;J Clin Oncol,1997

2. Marrow transplantation from related donors other than HLA-identical siblings;Beatty;N Engl J Med,1985

3. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse;Aversa;J Clin Oncol,2005

4. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States;Aversa;Bone Marrow Transplant,2008

5. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide;Luznik;Biol Blood Marrow Transplant,2008

Cited by 253 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation;Transplantation and Cellular Therapy;2024-09

2. Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide;Bone Marrow Transplantation;2024-08-24

3. Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation;Transplantation and Cellular Therapy;2024-08

4. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil;Transplantation and Cellular Therapy;2024-08

5. HLA evolutionary divergence (HED) informs the effect of HLA-B mismatch on outcomes after haploidentical transplantation;Bone Marrow Transplantation;2024-07-31